Host molecular and cellular responses to anti-cancer drug treatment as a potential biomarker for treatment outcome

Objetivo

Chemotherapy remains one of the most common treatment modalities for cancer. It is typically administered in cycles of bolus injections following 21 days of drug-free break periods. However, tumor regrowth between drug intervals is often observed, due in part, to rebound angiogenesis. Our previous studies demonstrated that bone marrow derived proangiogenic cells are acutely mobilized following certain chemotherapy treatments, accompanied by enhanced tumor angiogenesis, which can be blocked by prior treatment with antiangiogenic drugs. These findings indicate that unknown host-derived mechanisms induced by chemotherapy, can stimulate tumor growth. Since the efficacy of antiangiogenic drugs is dependent on several parameters such as tumor type, stage, and the type of chemotherapy, such a therapy is not beneficial for all patients, and thus, necessitates the identification of surrogate biomarkers to predict clinical outcome. To address this issue, we will integrate basic, translational, and clinical approaches to:
(i) identify molecular and cellular host systemic responses following treatments;
(ii) isolate novel factors by proteomic approaches which are altered during the course of the treatment, and evaluate their feasibility as biomarkers to predict clinical outcome;
(iii) determine the relevance of these factors in clinical specimens;
(iv) screen for therapeutic compounds which can block host responses mediating tumor growth in order to increase treatment efficacy.

We believe that this strategy of combined approach will lead to the development of new tools in clinical oncology. Profiling individual host response to anti-cancer drug treatment may serve as a biomarker for treatment outcome and further promote the concept of personalised medicine in cancer therapy.

Ámbito científico

Régimen de financiación

ERC-SG - ERC Starting Grant

Institución de acogida

TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY

Aportación de la UE

€ 1 499 622,00

Dirección

SENATE BUILDING TECHNION CITY
32000 Haifa
Israel

Tipo de actividad

Higher or Secondary Education Establishments

Contacto administrativo

Mark Davison (Mr.)

Investigador principal

Yuval Shaked (Dr.)

Enlaces

Contactar con la organización Sitio web

Coste total

Sin datos

Beneficiarios (1)